Dilated Cardiomyopathy Therapeutics Market Forecast to USD 300 Million by 2020 Owing to Drug Side Effects and Medical Devices Substitution - iHealthcareAnalyst, Inc.

Dilated Cardiomyopathy Therapeutics Market – Global DCM Drug Classes and Pipeline Analysis and Forecast 2013-2020

Maryland Heights, MO, July 15, 2016 --(PR.com)-- The global dilated cardiomyopathy therapeutics market is estimated to reach USD 300 Million in 2020, declining at a CAGR of 6.0% from 2016 to 2020, according to a new market research report Dilated Cardiomyopathy Therapeutics Market – Global DCM Drug Classes and Pipeline Analysis and Forecast 2013-2020, published by iHealthcareAnalyst, Inc.

Visit the Dilated Cardiomyopathy Therapeutics Market – Global DCM Drug Classes and Pipeline Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/dilated-cardiomyopathy-therapeutics-market/

Dilated cardiomyopathy or DCM is the most common form of non-ischemic cardiomyopathy condition that involves decreased heart function due to an enlarged heart which cannot pump blood efficiently and can affect the lungs, liver, and other body systems. Standard therapy may include salt restriction, ACE inhibitors, diuretics, and digitalis and anticoagulants may also be used. The global dilated cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (aldosterone antagonists, angiotensin ii receptor blockers, angiotensin-converting enzyme inhibitors, and beta-blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

The global dilated cardiomyopathy therapeutics market is segmented as:

1. Drug Class
1.1. Aldosterone Antagonists
1.2. Angiotensin II Receptor Blockers (ARBs)
1.3. Angiotensin-Converting Enzyme (ACE) Inhibitors
1.4. Beta-Blockers

2. Pipeline Analysis (Phase 3 Drugs)
2.1. ARRY-797
2.2. CAP-1002
2.3. ixCELL-DCM
2.5. OR-1

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Array BioPharma, Inc.
4.2. AstraZeneca plc.
4.3. Celladon Corporation
4.4. GlaxoSmithKline plc
4.5. Janssen Pharmaceuticals, Inc. (J&J)
4.6. Merck & Co., Inc.
4.7. Novartis International AG
4.8. Pfizer, Inc.
4.9. Sanofi S.A.
4.10. Teva Pharmaceutical Industries Ltd.
4.11. Vericel Corporation

About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294